Clearmind Medicine Inc. files Annual Report on Form 20-F for fiscal year ending Oct 31, 2025 with the SEC.
In Vancouver, Canada on January 20, 2026, Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) revealed the submission of its Annual Report on Form 20-F for the fiscal year concluding on October 31, 2025, to the U.S. Securities and Exchange Commission ('SEC'). The Company, a clinical-stage biotech entity concentrating on pioneering neuroplastogen-based therapeutics for significant undertreated health issues, made this announcement.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments